ABBISKO-B(02256.HK)

Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People’s Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal trial products comprising Mavorixafor (ABSK081), a CXCR4 modulator to treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome; and Irpagratinib (ABSK011), a small molecule inhibitor of FGFR4 for the treatment of advanced hepatocellular carcinoma. In addition, the company develops products in Phase Ib/II trial, such as Fexagratinib (ABSK091) for the treatment of urothelial carcinoma; ABSK061, a small molecule inhibitor targeting FGFR 2/3 to treat solid tumors and achondroplasia; and ABSK043, a PD-L1 inhibitor for the treatment of non-small cells lung cancer (NSCLC).